Immunogenicity Studies

Services and Capabilities 
Immunogenicity testing evaluates drug safety, and as such, these tests are essential components in the development of biotherapeutic drugs.

Cambridge Biomedical has developed and validated many different immunogenicity assays for the purposes of both clinical diagnostics and clinical trials, and against a variety of invading microorganisms in patient samples and administered drugs.

We can recommend strategies and provide contract services for assessing immunogenicity utilizing the following technologies:

     ELISA (Enzyme Linked Immunosorbent Assay)
     RIA (Radio Immunoassay)
     MSD (Mesoscale Discovery, Electrochemiluminescence)
     Binding assays
     Cell based neutralizing assays
     Flow cytometry

Immunogenicity Testing Services


NK cell killing (cytotoxicity)

Phagocytosis or Phagoburst (Neutrophils and Monocytes)

T cell proliferation

Cytokine analysis


Cambridge Biomedical is CLIA certified, CAP accredited, and provides services that support best laboratory practices and GLP compliance. We help you navigate through quality and regulatory requirements from preclinical to phase IV studies.

Latest News   

 Subscribe to our blog


Cambridge Biomedical's Biannual Scientific Meeting - Microbiome Luncheon

Tuesday, December 12, 2017  11:30AM to 1:00PM

Catalyst Restaurant                  300 Technology Square,   Cambridge MA 02139

For existing clients & test results please contact 
Customer Service:617.456.0800
All rights reserved. Cambridge Biomedical, the Cambridge Biomedical logo, Science and Service, and Custom
Solutions for Life Sciences Companies are registered or unregistered trademarks of Cambridge Biomedical Inc.
|     Privacy Statement     | Terms of Use